Navigation Links
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
Date:5/26/2009

SAN DIEGO, May 26 /PRNewswire/ -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical results from studies of TRC105 and TRC102 in patients with advanced cancer will be presented at the American Society of Clinical Oncology annual meeting this May 28th and 29th in Orlando, Florida. Both programs target unique pathways with the potential for broad application to a wide variety of cancer types.

TRC105 is a monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide variety of solid tumors that rely on angiogenesis to grow and metastasize. CD105 is also expressed on cancer stem cells.

TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent in combination with temozolomide (Temodar(R)).

"TRACON remains on schedule to deliver three Phase 2-ready assets in 2009 including two monoclonal antibodies," commented Charles P. Theuer MD PhD, President and CEO of TRACON Pharmaceuticals. "We are currently engaged in manufacturing and clinical development activities to support comprehensive Phase 2 programs."

The presentation details are as follows:

    TRC105
    Abstract Title: Phase 1 study of TRC105 (anti-CD105 (endoglin) antibody)
    therapy in patients with advanced refractory cancer
    Presenter: Lee Rosen, MD, Premiere Oncology - Los Angeles
    Date and Time: Friday, May 29, 2009, 2:00 PM - 6:00 PM
    Session Title: Developmental Therapeutics
    Session Type: Poster Discussion
    Abst
'/>"/>
SOURCE  TRACON Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 

Related medicine technology :

1. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
2. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
3. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
4. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
5. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
7. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... HARBIN, China , ... One,Medical, Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter,drugs in the People,s ... (Hocena) capsule, a new anti-cancer drug co-developed by ...
(Date:3/17/2010)... March 17 Kendle (Nasdaq: KNDL ), a leading, ... , Vice President, Asia/Pacific will address the World Pharma ... at the Raffles City Convention Centre in Singapore . Dr. ... scheduled for March 18 at 2 p.m. ...
(Date:3/17/2010)... , ... , ... ... SILVER SPRING, Md. , March 17 The U.S. Food and Drug Administration today ...
Breaking Medicine Technology:China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 2China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 3China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 4China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 5Kendle Executive to Share Insights at World Pharma Trials Asia 2010 2Kendle Executive to Share Insights at World Pharma Trials Asia 2010 3FDA Approves First Totally Implanted Hearing System 2FDA Approves First Totally Implanted Hearing System 3FDA Approves First Totally Implanted Hearing System 4FDA Approves First Totally Implanted Hearing System 5Solos Endoscopy Inc s Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine 6167 1Solos Endoscopy Inc s Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine 6167 2Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX 0401 28Perifosine 29 at the 51st Annual Meeting of the A 6163 1Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX 0401 28Perifosine 29 at the 51st Annual Meeting of the A 6163 2Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX 0401 28Perifosine 29 at the 51st Annual Meeting of the A 6163 3Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research 6159 1Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research 6159 2
... provides the foundation for improving understanding of N-myc,gene,s ... when,retinoblastoma forms, MEMPHIS, Tenn., Jan. 16 ... Children,s Research Hospital helps answer a,long-standing mystery about ... deeper understanding of how genes coordinate the complex ...
... a,biopharmaceutical company focused on the development of novel ... from its,Phase I safety and tolerability study of ... MRX-4 was nasally administered as a single ... first administration was given without a nasal,allergen challenge ...
Other Medicine Technology:St. Jude Defines Eye Cancer Gene's Role in Retinal Development 2St. Jude Defines Eye Cancer Gene's Role in Retinal Development 3Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients 2
(Date:3/18/2010)... WATERTOWN, Mass. , March 18 Bright Horizons Family Solutions ®, the world,s leading provider of employer-sponsored child care, early education, and work/life solutions, today ... ... ... ...
(Date:3/18/2010)... PH, President and CEO, Legacy(SM) , ... ... WASHINGTON , ... , ...
(Date:3/18/2010)... March 18, 2010 Two new studies show ... Eye Retroscope (TER), a retrograde viewing device, during colonoscopy. ... colonoscopy detected 13.2 percent more polyps than colonoscopy alone, ... study examined endoscopist experience using TER and its impact ...
(Date:3/18/2010)... how individual variation in gene regulation can have a lasting ... an ambitious survey of the human genome has identified differences ... DNA that affect how genes are expressed in different people. ... 18, 2010, issue of Science , looked at two ...
(Date:3/18/2010)... March 18 Yesterday, Idaho became ... to protect their citizens from being forced to purchase health ... will. The American Legislative Exchange Council (ALEC) has ... bills or have announced that they will introduce this legislation. ...
Breaking Medicine News(10 mins):Health News:Bright Horizons Honored as 'Company that Cares' for Third Straight Year 2Health News:Bright Horizons Honored as 'Company that Cares' for Third Straight Year 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Studies examine Third Eye Retroscope during colonoscopy 2Health News:Studies examine Third Eye Retroscope during colonoscopy 3Health News:Studies examine Third Eye Retroscope during colonoscopy 4Health News:Studies examine Third Eye Retroscope during colonoscopy 5Health News:Transcription factors may dictate differences between individuals 2Health News:Transcription factors may dictate differences between individuals 3Health News:Transcription factors may dictate differences between individuals 4Health News:Idaho Enacts Health Care Freedom Act 2Health News:Idaho Enacts Health Care Freedom Act 3Health News:Idaho Enacts Health Care Freedom Act 4Health News:Idaho Enacts Health Care Freedom Act 5
... Dec. 15 Students interested in pursuing careers in ... scholarship/loan through the North Carolina Student Loan Program for ... year at the college information site, CFNC.org. ... Carolina Student Loan Program for Health, Science and Mathematics ...
... W. Woodruff Foundation has pledged $3 million toward construction ... Dentistry building. , "This is great news for the ... demonstrate to other foundations and corporations, and to individuals, ... upon groundbreaking for the new building during the year ...
... Aurora Health Care announced today that,the physicians ... southeastern Wisconsin, have chosen to join Aurora Medical Group. , ... radiologists practice chiefly at Aurora hospitals and,clinics. , ... day contribute to the quality,of the care we provide for ...
... chocolate truffle can induce cravings for more sugary and ... products, according to a new study in the ... that examined goals and behavior in consumers, authors Juliano ... Florida) found that study participants who consumed a chocolate ...
... data provides increased transparency , , ... Shield is providing its members with online physician quality information ... care decisions. , , ... know where to obtain the best care at the best ...
... study confirms the efficacy of The Pink Patch for ... lbs. (2.7 kg) in 4 weeks. The Pink Patch ... achieve their weight loss goals. Dr. Hudson stated ... absence of any dietary or activity changes, The Pink ...
Other Medicine News:Health News:North Carolina Student Loan Program for Health, Science and Mathematics Application Will Be Available December 20, 2008 2Health News:Woodruff Foundation pledges $3 million toward MCG dental building 2Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:Slippery slope: 1 tiny truffle can trigger desire for more treats 2Health News:Highmark Blue Cross Blue Shield Provides Online Physician Quality Information to Members 2Health News:Double Blind Study Proves The Pink Patch Works for Weight Loss 2Health News:Double Blind Study Proves The Pink Patch Works for Weight Loss 3
7 1/2" Bayonet Monopolar Forceps, Ins., Serrated...
... the art in inverted microscopy from Zeiss. ... range of ICS objectives, with innovative condensers ... an unusual scope of sophisticated documentation and ... designed. And Axiovert 200 M, fully motorized, ...
... The new Eclipse TS100 is ... microscope. This high quality tool complements ... increased stability. Image Documentation: Nikon offers ... models. The TS100-F trinocular model comes ...
... camera with direct digital output. Three-chip color ... Olympus wide array of high-quality color video ... and flexibility you need for an efficient ... high-resolution, real-time image of your specimen that ...
Medicine Products: